Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
pneumococcal vaccine
Pharma
Merck's new Capvaxive scores key CDC vaccine panel endorsement
The recommendation sets up Merck's new pneumococcal disease vaccine to potentially capture some of Pfizer's market share.
Zoey Becker
Jun 28, 2024 11:44am
FDA signs off on Merck's pneumococcal vax for adults, Capvaxive
Jun 17, 2024 5:03pm
FDA signs off on Pfizer's Prevnar 20 to vaccinate infants
Apr 28, 2023 9:15am
FDA grants Pfizer's Prevnar 20 priority review for pediatric use
Jan 6, 2023 10:20am
Pfizer shows key data, setting up pediatric nod for Prevnar 20
Aug 12, 2022 10:50am
Merck's Prevnar rival snags key pediatric nod
Jun 22, 2022 6:45am
